10-K: BriaCell Reports Increased Net Loss Amid Clinical Progress

BriaCell Therapeutics Corp. reported a significantly increased net loss for fiscal year 2025, primarily due to warrant revaluation, while advancing its lead immunotherapy candidates in breast and prostate cancer trials.

Summary

• BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies for cancer, with lead candidates Bria-IMT, Bria-OTS, and Bria-PROS+.
• The company is advancing its Bria-IMT targeted immunotherapy in a pivotal Phase 3 study (NCT06072612) for metastatic breast cancer, which holds Fast Track Designation from the FDA.
• Phase 2 study data for Bria-IMT combination therapy showed a median overall survival of 13.4 months for all patients, and 16.5 months for patients treated with the Phase 3 formulation since 2022, outperforming historical benchmarks of 6.7-9.8 months.
• Bria-IMT plus CPI in HR+ metastatic breast cancer patients showed a median overall survival of 17.3 months, exceeding TRODELVY (14.4 months) and single-agent chemotherapy (11.3 months).
• In TNBC patients, Bria-IMT plus CPI showed a median overall survival of 13.9 months, also better than TRODELVY (11.8 months) and single-agent chemotherapy (6.9 months).
• Bria-IMT demonstrated a 71% intracranial overall response rate (iORR) in patients with measurable intracranial metastatic disease, significantly higher than typical rates of less than 20% in comparable patients.
• The Bria-OTS personalized off-the-shelf immunotherapy Phase 1/2 study (NCT06471673) is ongoing, with one patient achieving complete resolution of a lung metastasis sustained at 6 months.
• Bria-PROS+ for prostate cancer received positive Pre-IND feedback from the FDA, waiving requirements for animal toxicology and pharmacokinetic studies prior to IND opening.
• The company reported a net loss of $26,311,867 for the fiscal year ended July 31, 2025, compared to $4,791,466 in 2024.
• The increased net loss was primarily due to a significantly smaller gain on the fair value of warrant liability ($758,364 in 2025 vs. $28,242,472 in 2024), despite a reduction in operating expenses.
• Research and development expenses decreased to $21,270,678 in 2025 from $27,177,807 in 2024, mainly due to the conclusion of the Bria-IMT Phase 1/2a trial.
• General and administrative expenses were $5,934,125 in 2025, slightly down from $6,152,269 in 2024.
• The company's working capital improved from a negative $3,807,303 in 2024 to a positive $15,948,588 in 2025.
• Cash and cash equivalents increased to $10,493,808 in 2025 from $862,089 in 2024, largely due to $50.9 million in gross proceeds from equity financings during the year.
• The company has an accumulated deficit of $111,755,564 as of July 31, 2025, and faces substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 6

Explanation: While the net loss increased significantly due to warrant revaluation, the underlying operating loss decreased, and the company's liquidity improved substantially through successful capital raises. More importantly, there is strong positive clinical progress across multiple immunotherapy programs (Bria-IMT, Bria-OTS, Bria-PROS+), including benchmark-beating survival data and FDA Fast Track designation. The explicit 'going concern' risk is a major negative, but the recent financings and clinical milestones provide a more optimistic operational outlook despite the accounting loss.

Positives

• Bria-IMT Phase 3 study for metastatic breast cancer is ongoing with no safety concerns reported by the Data Safety Monitoring Board (DSMB).
• Bria-IMT has Fast Track Designation from the FDA, potentially accelerating review and approval.
• Phase 2 data for Bria-IMT combination therapy showed benchmark-beating median overall survival of 13.4 months (all patients) and 16.5 months (Phase 3 formulation post-2022) compared to 6.7-9.8 months in literature.
• Bria-IMT plus CPI demonstrated superior median overall survival in HR+ MBC (17.3 months) and TNBC (13.9 months) compared to TRODELVY and single-agent chemotherapy.
• High intracranial overall response rate (iORR) of 71% observed in Bria-IMT treated patients with brain metastases, significantly exceeding typical rates of less than 20%.
• Bria-OTS monotherapy showed complete resolution of a lung metastasis in the first treated patient, with sustained response at 6 months.
• Bria-OTS Phase 1/2 study cleared safety evaluation and has transitioned to combination dosing with an immune checkpoint inhibitor.
• Bria-PROS+ for prostate cancer received positive Pre-IND feedback from the FDA, including a waiver for animal toxicology and pharmacokinetic studies, accelerating its development pathway.
• The company's working capital significantly improved from negative $3,807,303 in 2024 to positive $15,948,588 in 2025.
• Cash and cash equivalents increased substantially to $10,493,808 in 2025 from $862,089 in 2024, bolstering liquidity.
• Successful capital raises totaling approximately $50.9 million in gross proceeds during fiscal year 2025.

Negatives

• The company reported a significantly increased net loss of $26,311,867 for the fiscal year ended July 31, 2025, compared to $4,791,466 in 2024.
• Accumulated deficit grew to $111,755,564 as of July 31, 2025, from $85,443,697 in 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows from operating activities.
• The company is a pre-revenue clinical stage company with an unproven market for its product candidates.

Risks

• Pre-clinical studies and initial clinical trials are not necessarily predictive of future results, and favorable early results may not be repeated in later, larger trials.
• Heavy reliance on third parties for manufacturing, pharmaceutical development, marketing, and clinical trials introduces risks of delays, failures, and inadequate performance.
• Development of novel technologies (immunotherapies) may not be effective or safe, or may not receive regulatory approval.
• Inability to successfully develop, maintain, and protect proprietary products and technologies, including challenges to patents or intellectual property infringement claims.
• If the FDA or comparable foreign regulatory authorities approve generic versions of products or do not grant appropriate exclusivity periods, sales could be adversely affected.
• Changes in legislation and regulations may affect revenue and profitability, increasing compliance costs or leading to enforcement actions.
• Substantial doubt about the company's ability to continue as a going concern due to significant losses and dependence on future financing.
• High dependence on key personnel, with the loss of any key individual potentially having a material adverse effect.
• An unproven market for product candidates, with no assurance of commercial viability or market acceptance.
• Anticipated growth will place significant strain on managerial, operational, financial, and technical resources, requiring effective management of expansion and external partnerships.
• BriaPro, a majority-owned subsidiary, may not generate expected revenue or financial returns, potentially leading to impairment charges and erosion of value.
• Data security breaches and cyber-attacks could lead to penalties, negative publicity, and disruption of business operations.
• International operations expose the company to risks such as country-specific taxation, governmental controls, trade restrictions, and difficulties in collecting receivables.
• Failure to comply with Nasdaq or TSX listing requirements could lead to delisting, reducing liquidity and market price of common shares.
• Future issuance of common shares could dilute existing shareholders' interests and adversely affect the market price.
• Short sellers may manipulate and drive down the market price of common shares through negative publications.
• A significant number of outstanding restricted share units, options, and warrants may make it more difficult to raise additional equity capital without substantial dilution.
• If classified as a passive foreign investment company (PFIC), U.S. shareholders may suffer adverse tax consequences.
• Global economic uncertainty, financial market volatility, and geopolitical conflicts could make it difficult to access financing and disrupt operations.
• Adverse effects of inflation, including increased costs of labor, materials, and capital, could impact financial performance.

Future Outlook

BriaCell anticipates reporting top-line data for its pivotal Phase 3 Bria-IMT study as early as H1-2026. IND filings for Bria-OTS+ enhanced immunotherapy cell lines (Bria-PROS+, Bria-LUNG+, Bria-MEL+, Bria-BRES+) are expected to commence in late 2025 or early 2026. BriaPro expects to screen several multi-specific binding reagents for in vitro and mouse model activity and select at least one candidate for IND-enabling studies, with human clinical studies expected to be initiated in H1-2025. BriaPro also plans to optimize protein kinase C delta inhibitors and advance to candidate selection, with human clinical studies expected in H2-2025.

Management Comments

• Management believes that its current cash and cash equivalent reserves will be sufficient to meet its anticipated needs for working capital and capital expenditures for the near future.
• Management believes it can be successful in obtaining additional capital, but there can be no assurance that the Company will be able to do so.
• Certain directors and officers agreed to defer payment of their fees/compensation until a financing was completed, after which these fees were paid in full.
• Certain officers have indicated their willingness to receive a portion of their compensation in shares of the Company, subject to applicable Nasdaq rules.
• The company continues to reduce expenditure on certain non-core activities whilst maintaining its focus on the Phase 3 Bria-IMT pivotal study.

Industry Context

The global market for cancer drugs, including immunotherapy, is projected to reach nearly $441 billion by the end of 2029, indicating significant growth potential. BriaCell's focus on novel immunotherapies for metastatic breast and prostate cancer addresses areas of high unmet medical need, particularly for patients who have failed multiple prior lines of therapy. The company's strategy of combining its therapies with immune checkpoint inhibitors aligns with a growing trend in immuno-oncology. The use of AI in drug discovery by its subsidiary BriaPro also reflects a broader industry shift towards leveraging advanced technologies to accelerate development.

Comparison to Industry Standards

• BriaCell's Bria-IMT combination therapy in its Phase 2 study demonstrated a median overall survival of 13.4 months for all patients, and 16.5 months for patients treated with the Phase 3 formulation since 2022, which compares favorably to reported median overall survival rates of 6.7-9.8 months for similar metastatic breast cancer patients in the literature (Cortes J, et al. Annals of Oncology 2018; Kazmi S, et al. Breast Cancer Res Treat. 2020 Aug 17; OShaughnessy J et al. Breast Cancer Res Treat. 2022; Tripathy D, et al. JAMA Oncol. 2022).
• In hormone receptor positive (HR+) metastatic breast cancer, Bria-IMT plus CPI achieved a median overall survival of 17.3 months, exceeding the current ADC standard of care TRODELVY (sacituzumab govitecan-hziy) at 14.4 months and single-agent chemotherapy at 11.3 months.
• For triple-negative breast cancer (TNBC) patients, Bria-IMT plus CPI showed a median overall survival of 13.9 months, which was better than TRODELVY (11.8 months) and markedly higher than single-agent chemotherapy (6.9 months).
• The intracranial overall response rate (iORR) of 71% for Bria-IMT in patients with measurable intracranial metastatic disease compares very favorably with typical iORR rates of less than 20% in comparable patients treated with systemic therapy (Niwinska A, et al. Cancers (Basel). 2022; Tripathy D, et al. JAMA Oncol. 2022).

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings are pending against the Company.

Related Party Transactions

• On May 17, 2024, the company issued and sold 6,019 common shares together with warrants to purchase up to 6,019 common shares to a former director at a combined purchase price of $332.25 per share and accompanying warrant.
• On January 16, 2025, the Company granted 5,833 Restricted Share Units (RSUs) to the Chief Executive Officer as compensation for deferred salary, with a fair value of $350,000, immediately vesting and offsetting previously accrued compensation.
• Certain directors and officers agreed to defer payment of their directors fees/compensation for several months during calendar year 2025 until a financing was completed, after which these fees were paid in full.
• Certain officers have indicated their willingness to receive a portion of their compensation in shares of the Company, subject to applicable Nasdaq rules.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity financings and exercise of outstanding options/warrants. Risk of share price volatility due to market conditions, short-seller activity, and delisting concerns. Positive clinical trial results could drive value appreciation. The spin-out of BriaPro created a new unlisted reporting issuer, with one-third ownership distributed to shareholders.
• Employees: Increased wages and salaries for some, but also reliance on key personnel. Share-based compensation is a component of executive and director remuneration. Potential for job growth with anticipated business expansion.
• Customers/Patients: Development of novel immunotherapies aims to provide improved therapeutic options for patients with advanced breast and prostate cancer, addressing unmet medical needs.
• Suppliers/Contractors: Continued reliance on third-party contract manufacturers and research organizations for raw materials, manufacturing, and clinical trial services. Collaboration with Prevail InfoWorks, Inc. for clinical services.
• Creditors: The company's ability to continue as a going concern is dependent on securing additional financing, which could impact creditors if not successful. Improved working capital and cash position enhance short-term financial stability.

Next Steps

• Continue pivotal Phase 3 clinical testing of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer.
• Submit a Biologics License Application (BLA) for Bria-IMT combination following positive completion and FDA review of the pivotal study.
• Continue Phase 1/2 study of Bria-OTS in metastatic breast cancer, including combination dosing with immune checkpoint inhibitors.
• Initiate IND filings for Bria-OTS+ enhanced immunotherapy cell lines (Bria-PROS+, Bria-LUNG+, Bria-MEL+, Bria-BRES+) starting in late 2025 or early 2026.
• Advance Bria-PROS+ for prostate cancer into a Phase 1/2a clinical trial, funded by the NCI grant.
• BriaPro to screen multi-specific binding reagents and select a candidate for IND-enabling studies, with human clinical studies expected in H1-2025.
• BriaPro to optimize protein kinase C delta inhibitors and advance to candidate selection, with human clinical studies expected in H2-2025.
• Actively pursue strategies to mitigate going concern risks, focusing on revenue generation and expanding the customer base.
• Manage expanding operations, including attracting and retaining qualified personnel, and improving operational and financial systems.

Key Dates

Recommendation

BriaCell presents a complex investment profile. The company is in a pre-revenue stage with a significant accumulated deficit and an explicit 'going concern' risk, which are major red flags for investors. However, the company has demonstrated strong operational progress, particularly in its clinical pipeline. The Bria-IMT Phase 3 study is advancing with positive safety reviews and promising Phase 2 data showing superior overall survival compared to benchmarks. The Bria-OTS program is also showing early positive clinical responses, and Bria-PROS+ has received favorable FDA feedback. Recent capital raises have significantly improved the company's liquidity and working capital, providing runway for ongoing trials. For a seasoned investor, the high risk associated with a clinical-stage biotech company and the going concern warning is balanced by the compelling clinical data and the potential for significant upside if Bria-IMT achieves regulatory approval. The stock is highly speculative, but the recent positive clinical and financing news suggests maintaining a position to observe upcoming milestones, particularly the H1-2026 top-line data for the pivotal Phase 3 study, rather than exiting or significantly increasing exposure at this juncture.

Keywords

Immunotherapy, Breast Cancer, Metastatic Breast Cancer, Prostate Cancer, Bria-IMT, Bria-OTS, Bria-PROS+, Clinical Trials, Phase 3, Fast Track Designation, Oncology, Biotechnology, SEC Filing, 10-K, Cancer Treatment, Cellular Therapy, Immune Checkpoint Inhibitor, FDA Approval, Biologics License Application, NASDAQ, TSX